|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYC encodes a transcriptional activator and amplification may adversely affect survival in small-cell lung cancer (SCLC).
|
9508209 |
1998 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A sensitive nonradioactive ribunuclease protection assay is described which we have used to study c-myc gene transcription and promoter usage in GLC4, a human small cell lung carcinoma cell line with amplified gene.
|
1333951 |
1993 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All-trans-retinoic acid alters myc gene expression and inhibits in vitro progression in small cell lung cancer.
|
8123593 |
1994 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on a recent study that identified the spliceosome as a therapeutic vulnerability in MYC-driven breast cancers, we evaluated the efficacy of a spliceosome inhibitor in SCLC cell lines and analyzed the correlation with MYC status.
|
28192473 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.
|
16116477 |
2006 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Control of the MYC-eIF4E axis may be a novel therapeutic strategy for everolimus action in SCLC.
|
25884680 |
2015 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytogenetic abnormalities in human small cell lung carcinoma: cell lines characterized for myc gene amplification.
|
2830010 |
1988 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emerging target treatments associated with MYC status in SCLC necessitates the evaluation of MYC using current methodologies, such as CISH.
|
25012251 |
2014 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genetic and pharmacological inhibition of MYC in SCLC cells to non-TPC levels inhibits long-term propagation but not short-term growth.
|
27373157 |
2016 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In MYC-amplified SCLC cells Aurora kinase inhibition associates with G2/M-arrest, inactivation of PI3-kinase (PI3K) signaling, and induction of apoptosis.
|
23035247 |
2012 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a small-cell lung carcinoma (SCLC) tumor specimen as well as in 3 cell lines derived from SCLC biopsies obtained from the same patient at successive times during the clinical course, either the N-myc gene or the c-myc gene appeared to be amplified and expressed.
|
2545636 |
1989 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the 9p24.1 region was identified as being amplified in SCLCs without amplification of MYC family oncogenes.
|
23716474 |
2013 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, CN alterations of the TP53 gene and the MYC family members were predominantly observed in SCLC.
|
20615970 |
2010 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this issue of Cancer Discovery, Romero and colleagues identify somatic mutations and deletions of MAX, and also define what seem to be mutually exclusive alterations in MYC family members and other MYC-associated factors in small cell lung cancer.
|
24596200 |
2014 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we will compare the distinct molecular features of the 3 MYC family members and address the potential implications for targeted therapy of SCLC.
|
28737478 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In vivo experiments with two SCLC xenograft models confirmed the sensitivity of Myc gene-driven models to PF-03814735 and a possible schedule dependence of MYC/c-Myc-driven tumors.
|
22222631 |
2012 |
|
Small cell carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MYCN, a member of the MYC family, is correlated with tumorigenesis, metastasis and therapy in many malignancies; however, its role in small-cell lung cancer (SCLC) remains unclear.
|
31598396 |
2019 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Of interest, 5 SCLC lines with high levels of myc gene family expression related to c-, N-, or L-myc gene amplification exhibited growth inhibition (28-87%), whereas 2 non-SCLC lines actually showed growth stimulation after treatment with 1 microM RA.
|
8274449 |
1993 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results strongly indicate that SCLC cells carrying amplification of MYC, MYCL or MYCN are addicted to MYC function, suggesting that MYC targeting would be an efficient therapeutic option for SCLC patients.
|
27105536 |
2016 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide.
|
24058603 |
2013 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Proteomic analysis identified CHK1 and MYC as top predictive biomarkers of LY2606368 sensitivity, suggesting that CHK1 inhibition may be especially effective in SCLC with <i>MYC</i> amplification or MYC protein overexpression.
|
28490518 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Surprisingly, in two cell lines with low neuroendocrine differentiation but without c-myc protein expression (SCLC-86M1 and NCI-H526) p75c-myb expression was observed which may therefore be able to substitute for the p64c-myc protein.
|
2536917 |
1989 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Targeted drug screening reveals that SCLC with high MYC expression is vulnerable to Aurora kinase inhibition, which, combined with chemotherapy, strongly suppresses tumor progression and increases survival.
|
28089889 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting the glutaminolysis pathway might hence be a novel approach to selectively kill MYC amplified SCLC cells in vivo.
|
28430666 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The activity of the myc gene family may contribute to certain biological characteristics of SCLC.
|
2833350 |
1988 |